Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243396 | 1.00 | CA2 (0.49) | CA2CA1TSHRGRIK1GRIK2 | |
| SCHEMBL244420 | 1.00 | CA2 (0.49) | CA2CA1TSHRGRIK1GRIK2 | |
| SCHEMBL243551 | 1.00 | CA2 (0.49) | CA2CA1TSHRGRIK1GRIK2 | |
| SCHEMBL244615 | 0.92 | CNR2 (0.43) | CA2CA1TSHR | |
| SCHEMBL244515 | 0.92 | CNR2 (0.43) | CA2CA1TSHR | |
| SCHEMBL244705 | 0.92 | CNR2 (0.43) | CA2CA1TSHR | |
| SCHEMBL245215 | 0.91 | TSHR (0.49) | CA2CA1TSHRGRIK1GRIK2 | |
| SCHEMBL245108 | 0.91 | TSHR (0.49) | CA2CA1TSHRGRIK1GRIK2 | |
| SCHEMBL244707 | 0.91 | TSHR (0.49) | CA2CA1TSHRGRIK1GRIK2 | |
| SCHEMBL245076 | 0.91 | TSHR (0.49) | CA2CA1TSHRGRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221738-B2 | Method and system for purifying monomers | EVONIK RÖHM GMBH (DE) | 2015-12-29 | — | — | US | disclosed |
| US-8420709-B2 | Coating composition, (meth)acrylic polymer and monomer mixture for producing the (meth)acrylic polymer | EVONIK RÖHM GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8415422-B2 | (Meth)acrylate monomer, polymer and coating agent | EVONIK RÖHM GMBH (DE) | 2013-04-09 | — | — | US | disclosed |
| US-20120065322-A1 | (METH)ACRYLATE POLYMER, COATING AGENT, METHOD FOR PRODUCING A COATING, AND COATED OBJECT | EVONIK ROEHM GMBH (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20120016071-A1 | POLYFUNCTIONAL (METH)ACRYLIC POLYMER, COATING COMPOSITION, PROCESS FOR PRODUCING A COATING AND COATED ARTICLE | EVONIK ROEHM GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120000764-A1 | METHOD AND SYSTEM FOR PURIFYING MONOMERS | EVONIK DEGUSSA GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20110318595-A1 | COATING COMPOSITION, (METH)ACRYLIC POLYMER AND MONOMER MIXTURE FOR PRODUCING THE (METH)ACRYLIC POLYMER | EVONIK ROEHM GMBH (DE) | 2011-12-29 | — | — | US | disclosed |
| US-20110144267-A1 | FUNCTIONALIZED (METH)ACRYLATE MONOMER, POLYMER, COATING AGENT, AND PRODUCTION AND CROSS-LINKING METHOD | EVONIK ROEHM GMBH (DE) | 2011-06-16 | — | — | US | disclosed |
| US-20110130509-A1 | (METH)ACRYLATE MONOMER, POLYMER AND COATING AGENT | EVONIK ROEHM GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110039977-A1 | AQUEOUS DISPERSIONS COMPRISING AT LEAST ONE ALKYD RESIN | EVONIK ROEHM GMBH (DE) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144267-A1 | FUNCTIONALIZED (METH)ACRYLATE MONOMER, POLYMER, COATING AGENT, AND PRODUCTION AND CROSS-LINKING METHOD | DNMT1, TET1, MGMT | CA2 3110/4885CA1 1608/4885TSHR 2023/4885 |
| US-20110130509-A1 | (METH)ACRYLATE MONOMER, POLYMER AND COATING AGENT | MGMT, DNMT1, TET1 | CA2 3501/4885CA1 3171/4885TSHR 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.